Comparison · NCT04806451-sae
DB Period: Crinecerfont vs DB Period: Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DB Period: Crinecerfont vs DB Period: Placebo: serious adverse events. Trial comparisons, record NCT04806451-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04806451-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0145 | 0.00256 | 0.0776 | wilson | |
| Risk in group 2 | 0.121 | 0.0482 | 0.273 | wilson | |
| Risk difference, group 1 minus group 2 | -0.107 | -0.259 | -0.0102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.12 | 0.0139 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.107 | 0.0114 | 0.996 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on DB Period: Crinecerfont than on DB Period: Placebo | 9.37 | 3.86 | 98.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DB Period: Crinecerfont | Participants received crinecerfont orally twice daily for 28 weeks during the DB placebo-controlled treatment period. Dose assignment from Day 1 to Week 28 was based on the participant's weight at Day 1. | 1 | 69 | EG001 |
| Group 2 | DB Period: Placebo | Participants received crinecerfont-matched placebo orally twice daily for 28 weeks during the DB placebo-controlled treatment period. | 4 | 33 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to Week 28
Source ClinicalTrials.gov
Trial
- Title
- Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
- NCT number
- NCT04806451
- Phases
- PHASE3
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Crinecerfont, Placebo
- Lead sponsor
- Neurocrine Biosciences
- Results first posted
- 2025-02-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04806451?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04806451-sae